News
-
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Announces Brokered LIFE Financing
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Files US Patent for Enhanced Immunotherapy
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Grants Stock Options
-
COMMUNIQUÉ DE PRESSE
Theralase(R) Closes Private Placement Equity Financing
-
COMMUNIQUÉ DE PRESSE
Theralase Release’s 2Q2023 Interim Financial Statements